Stephen E. Maxwell
Schering-Plough
6 Papers
37 Citations
Stephen E. Maxwell is an academic researcher from Schering-Plough. The author has contributed to research in topics: Ezetimibe & Cholesterol absorption inhibitor. The author has an hindex of 6, co-authored 6 publications.
Chat about Author
Papers
Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin
Teddy Kosoglou,Ingo Meyer,Enrico P. Veltri,Paul Statkevich,Bo Yang,Yali Zhu,L. Mellars,Stephen E. Maxwell,James E. Patrick,David L. Cutler,Vijay Batra,Melton B. Affrime +11 more
TL;DR: The coadministration of ezetimibe at doses up to 10 mg with simVastatin 10 or 20 mg daily was well tolerated and caused a significant additive reduction in LDL-C compared with simvastatin alone, while reported side-effects were generally mild, nonspecific, and similar among treatment groups.
Pharmacodynamic interaction between ezetimibe and rosuvastatin
Teddy Kosoglou,Paul Statkevich,Bo Yang,Ramachandran Suresh,Yali Zhu,Tanya Boutros,Stephen E. Maxwell,Renger G. Tiessen,David L. Cutler +8 more
TL;DR: Co-administering ezetimibe and rosuvastatin was well tolerated in patients with hypercholesterolemia and caused a significantly greater reduction in LDL-C and total cholesterol than either drug alone.
65
Interaction of Single-Dose Ezetimibe and Steady-State Cyclosporine in Renal Transplant Patients
Arthur J. Bergman,Joanne Burke,Patrick Larson,Amy O. Johnson-Levonas,Larisa Reyderman,Paul Statkevich,Stephen E. Maxwell,Teddy Kosoglou,Gail Murphy,Keith Gottesdiener,Richard Robson,John F. Paolini +11 more
TL;DR: Compared to healthy controls, EZE‐total AUC(0‐last) was 3.4‐fold higher in transplant patients receiving CyA; similar exposure levels were seen in a prior multiple‐dose study in which EZE 50 mg was administered to healthy volunteers without dose‐related toxicity.
37
Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin.
Teddy Kosoglou,Paul Statkevich,Ingo Meyer,David L. Cutler,Bernhard Musiol,Bo Yang,Yali Zhu,Stephen E. Maxwell,Enrico P. Veltri +8 more
TL;DR: The co-administration of ezetimibe and lovastatin has the potential to produce clinically significant reductions in LDL-C compared to either drug alone, with favorable safety and tolerability.
24
The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe.
TL;DR: Coadministration of ezetimibe and fluvastatin was safe and well tolerated and caused significant incremental reductions in LDL‐C and total cholesterol compared to fluvastsatin administered alone.
15